drugset / Trial / NCT02653417
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.
Timeline
- Start
- 2015-12
- Primary completion
- 2016-12-12
- Completion
- 2018-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 5 mg | — |
| Subject | Elacestrant | Other / unclassified | 10 mg | — |
| Subject | Elacestrant | Other / unclassified | 20 mg | — |
Indications
No indication recorded.